Latest Tyrosine kinase inhibitors Stories
A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.
SINGAPORE, Nov. 22, 2010 /PRNewswire/ -- S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial.
Results from Phase II biomarker analysis of erlotinib in combination with sorafenib presented at Molecular Targets in Cancer Therapeutic meeting in Berlin, Germany. Broomfield, CO (Vocus) November 19, 2010 Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in...
NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
Scientists believe they may have found a new target for treating triple negative breast cancer â€“ one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.
BROOMFIELD, Colo., Nov. 10, 2010 /PRNewswire/ -- Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, lead by existing investors.
BEIJING, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc.
Patients with rare type of leukemia now have another treatment option SILVER SPRING, Md., Oct. 28 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed.
A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib.
- A trick or prank.